$837 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 17 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ODT | ODONATE THERAPEUTICS INC | $456,742,000 | +24.7% | 14,075,269 | 0.0% | 54.57% | -12.9% | |
| HRTX | Sell | HERON THERAPEUTICS INC | $117,904,000 | +15.6% | 5,017,203 | -9.0% | 14.09% | -19.3% |
| RCKT | ROCKET PHARMACEUTICALS INC | $67,494,000 | +95.4% | 2,965,485 | 0.0% | 8.06% | +36.4% | |
| RLMD | New | RELMADA THERAPEUTICS INC | $50,700,000 | – | 1,300,000 | +100.0% | 6.06% | – |
| EOLS | New | EVOLUS INC | $32,068,000 | – | 2,635,000 | +100.0% | 3.83% | – |
| ANAB | New | ANAPTYSBIO INC | $29,962,000 | – | 1,843,814 | +100.0% | 3.58% | – |
| AVRO | Buy | AVROBIO INC | $20,130,000 | +71.9% | 1,000,000 | +20.6% | 2.40% | +20.1% |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $19,410,000 | -55.3% | 4,938,893 | 0.0% | 2.32% | -68.8% | |
| REGN | New | REGENERON PHARMACEUTICALS | $16,897,000 | – | 45,000 | +100.0% | 2.02% | – |
| BMY | New | BRISTOL MYERS SQUIBB CO | $7,179,000 | – | 111,844 | +100.0% | 0.86% | – |
| PRTA | PROTHENA CORP PLC | $6,709,000 | +101.9% | 423,823 | 0.0% | 0.80% | +40.9% | |
| GTHX | Buy | G1 THERAPEUTICS INC | $4,493,000 | +31.5% | 170,000 | +13.3% | 0.54% | -8.2% |
| PBYI | PUMA BIOTECHNOLOGY INC | $3,057,000 | -18.7% | 349,400 | 0.0% | 0.36% | -43.2% | |
| ISEE | Sell | IVERIC BIO INC | $2,145,000 | +219.2% | 250,000 | -58.3% | 0.26% | +122.6% |
| NCNA | Sell | NUCANA PLCsponsored adr | $1,525,000 | -57.9% | 250,000 | -50.0% | 0.18% | -70.6% |
| BMYRT | New | BRISTOL MYERS SQUIBB COright 99/99/9999 | $337,000 | – | 111,844 | +100.0% | 0.04% | – |
| EIDX | New | EIDOS THERAPEUTICS INC | $217,000 | – | 3,783 | +100.0% | 0.03% | – |
| CLRB | Exit | CELLECTAR BIOSCIENCES INC | $0 | – | -235,701 | -100.0% | -0.08% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -111,844 | -100.0% | -1.90% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.